304 related articles for article (PubMed ID: 33536184)
1. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study.
Weill A; Nguyen P; Labidi M; Cadier B; Passeri T; Duranteau L; Bernat AL; Yoldjian I; Fontanel S; Froelich S; Coste J
BMJ; 2021 Feb; 372():n37. PubMed ID: 33536184
[TBL] [Abstract][Full Text] [Related]
2. Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.
Samarut E; Lugat A; Amelot A; Scharbarg E; Hadjadj S; Primot C; Loussouarn D; Thillays F; Buffenoir K; Cariou B; Drui D; Roualdes V
J Neurooncol; 2021 Mar; 152(1):115-123. PubMed ID: 33392938
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.
Lee KS; Zhang JJY; Kirollos R; Santarius T; Nga VDW; Yeo TT
Sci Rep; 2022 Feb; 12(1):1942. PubMed ID: 35121790
[TBL] [Abstract][Full Text] [Related]
4. Preliminary report of patients with meningiomas exposed to Cyproterone Acetate, Nomegestrol Acetate and Chlormadinone Acetate - Monocentric ongoing study on progestin related meningiomas.
Devalckeneer A; Aboukais R; Bourgeois P; De Witte O; Racape J; Caron S; Perbet R; Maurage CA; Lejeune JP
Clin Neurol Neurosurg; 2021 Nov; 210():106959. PubMed ID: 34592677
[TBL] [Abstract][Full Text] [Related]
5. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study.
Gil M; Oliva B; Timoner J; Maciá MA; Bryant V; de Abajo FJ
Br J Clin Pharmacol; 2011 Dec; 72(6):965-8. PubMed ID: 21627676
[TBL] [Abstract][Full Text] [Related]
6. Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient.
Cebula H; Pham TQ; Boyer P; Froelich S
Acta Neurochir (Wien); 2010 Nov; 152(11):1955-6. PubMed ID: 20811919
[No Abstract] [Full Text] [Related]
7. Probable Drug-Related Meningioma Detected During the Course of Medication Review Services.
Alderman CP
Consult Pharm; 2016 Sep; 31(9):500-4. PubMed ID: 27636874
[TBL] [Abstract][Full Text] [Related]
8. Risk of intracranial meningioma with three potent progestogens: A population-based case-control study.
Hoisnard L; Laanani M; Passeri T; Duranteau L; Coste J; Zureik M; Froelich S; Weill A
Eur J Neurol; 2022 Sep; 29(9):2801-2809. PubMed ID: 35621369
[TBL] [Abstract][Full Text] [Related]
9. Cyproterone acetate and risk of meningioma: a nationwide cohort study.
Mikkelsen AP; Greiber IK; Scheller NM; Hilden M; Lidegaard Ø
J Neurol Neurosurg Psychiatry; 2022 Feb; 93(2):222-223. PubMed ID: 34187864
[No Abstract] [Full Text] [Related]
10. [Cyproterone acetate and meningioma: The latest findings].
Schmutz JL
Ann Dermatol Venereol; 2018 May; 145(5):390-391. PubMed ID: 29703641
[No Abstract] [Full Text] [Related]
11. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review.
Mancini I; Rotilio A; Coati I; Seracchioli R; Martelli V; Meriggiola MC
Gynecol Endocrinol; 2018 Jun; 34(6):456-459. PubMed ID: 29105524
[TBL] [Abstract][Full Text] [Related]
12. Abrupt regression of a meningioma after discontinuation of cyproterone treatment.
Gonçalves AM; Page P; Domigo V; Méder JF; Oppenheim C
AJNR Am J Neuroradiol; 2010 Sep; 31(8):1504-5. PubMed ID: 20053802
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and Progesterone Therapy and Meningiomas.
Hage M; Plesa O; Lemaire I; Raffin Sanson ML
Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34935947
[TBL] [Abstract][Full Text] [Related]
14. First case of cyproterone acetate induced multiple meningiomas in identical female twins: A case report.
Batchinsky-Parrou V; Barraud S; Kleiber JC; Litre F
Neurochirurgie; 2022 Apr; 68(3):323-326. PubMed ID: 33989640
[TBL] [Abstract][Full Text] [Related]
15. Use of progestogens and the risk of intracranial meningioma: national case-control study.
Roland N; Neumann A; Hoisnard L; Duranteau L; Froelich S; Zureik M; Weill A
BMJ; 2024 Mar; 384():e078078. PubMed ID: 38537944
[TBL] [Abstract][Full Text] [Related]
16. Hormonal therapies and meningioma: is there a link?
Cea-Soriano L; Blenk T; Wallander MA; Rodríguez LA
Cancer Epidemiol; 2012 Apr; 36(2):198-205. PubMed ID: 21943794
[TBL] [Abstract][Full Text] [Related]
17. Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization.
Passeri T; Giammattei L; Le Van T; Abbritti R; Perrier A; Wong J; Bourneix C; Polivka M; Adle-Biassette H; Bernat AL; Masliah-Planchon J; Mandonnet E; Froelich S
Acta Neurochir (Wien); 2022 Jan; 164(1):255-263. PubMed ID: 34613529
[TBL] [Abstract][Full Text] [Related]
18. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy.
Gazzeri R; Galarza M; Gazzeri G
N Engl J Med; 2007 Dec; 357(23):2411-2. PubMed ID: 18057351
[No Abstract] [Full Text] [Related]
19. Cyproterone acetate and meningioma: a nationwide-wide population based study.
Champeaux-Depond C; Weller J; Froelich S; Sartor A
J Neurooncol; 2021 Jan; 151(2):331-338. PubMed ID: 33394263
[TBL] [Abstract][Full Text] [Related]
20. Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome.
Graillon T; Boissonneau S; Appay R; Boucekine M; Peyrière H; Meyer M; Farah K; Albarel F; Morange I; Castinetti F; Brue T; Fuentes S; Figarella-Branger D; Cuny T; Dufour H
Neurochirurgie; 2021 Nov; 67(6):556-563. PubMed ID: 33989642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
